NovoCure Ltd. (038)
XDUS 
Summary
038 Chart
NovoCure (NVCR) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release
NovoCure (NVCR) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
NovoCure: 'Buy' TRIDENT Setback And TTFields FDA Decision Q4 2026
NovoCure Limited is downgraded from Strong Buy to Buy after the phase 3 TRIDENT trial failed to meet its primary endpoint of OS in newly diagnosed GBM patients. Company maintains growth potential with positive phase 2 PANOVA-4 results in mPDAC, ongoing KEYNOTE D58 trial in GBM, and an upcoming FDA decision for NSCLC brain metastases in Q4 2026. Q1 2026 net revenues rose 12% to $174 million, driven by Optune Gio, with full-year 2026 revenue guidance raised to $690–$710 million.
NovoCure's Cancer Treatment Device Option Pax Gets European Approval
NVCR secures European approval for Optune Pax, expanding access to its pancreatic cancer treatment after strong late-stage trial results.
NovoCure Ltd. (038) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
Has NovoCure Ltd. ever had a stock split?
NovoCure Ltd. Profile
| Electronic Equipment, Instruments & Components Industry | Information Technology Sector | Frank Leonard CEO | XDUS Exchange | JE00BYSS4X48 ISIN |
| CH Country | 1,605 Employees | - Last Dividend | - Last Split | 2 Oct 2015 IPO Date |
Overview
NovoCure Limited is a pioneering oncology company that specializes in the development, manufacture, and commercialization of its innovative tumor treating fields (TTFields) devices for the treatment of various solid tumor cancers. Founded in 2000, NovoCure maintains a strong international presence with operations in the United States, Germany, Japan, Greater China, and other global markets. The company is headquartered in Saint Helier, Jersey, highlighting its global reach and commitment to advancing cancer treatment worldwide. NovoCure's groundbreaking approach focuses on utilizing TTFields technology to target cancer cells, offering a novel treatment option beyond traditional methods. With ongoing clinical trials aimed at expanding the applications of TTFields, NovoCure continues to explore the potential of its technology in treating a wide range of cancers, including brain metastases, gastric cancer, glioblastoma, liver cancer, non-small cell lung cancer, pancreatic cancer, and ovarian cancer.
Products and Services
- Optune Gio:
- Optune Lua:
Optune Gio is one of NovoCure's flagship TTFields devices, designed specifically for the treatment of glioblastoma, a highly aggressive form of brain cancer. This device represents a significant advancement in the field of oncology, offering a non-invasive treatment option that utilizes low-intensity electric fields to disrupt cancer cell division and growth. By targeting glioblastoma cells while sparing healthy tissue, Optune Gio offers a promising treatment alternative for patients with this challenging condition.
Optune Lua is another innovative TTFields device offered by NovoCure, tailored for the treatment of malignant pleural mesothelioma, a rare cancer linked to asbestos exposure that affects the lining of the lungs. Like Optune Gio, Optune Lua employs TTFields technology to selectively target cancer cells, aiming to inhibit their proliferation and induce cell death. This device provides a critical option for mesothelioma patients, for whom treatment options are often limited and prognosis is typically poor.
